Junshi Biosciences Announces 2025 Interim Financial Results and Provides Corporate Updates

FINANCIAL HIGHLIGHTSAs of June 30, 2025, the total revenue of Junshi Biosciences was approximately RMB1,168 million for the first half of 2025, representing an increase of approximately 49% compared to 2024, driven mainly by pharmaceutical sales. In particular, the domestic sales revenue of our core product, TUOYI ®(toripalimab), reached approximately RMB954 million, an increase of approximately 42% from 2024.Total research and development (“R&D”) expenses of the company were...

SHANGHAI, 27/08/2025 (informazione.news - comunicati stampa - salute e benessere)

FINANCIAL HIGHLIGHTS

BUSINESS HIGHLIGHTS

During the first half of 2025, we focused on addressing “unmet medical needs”. We have made original, innovative and breakthrough progress in the discovery, R&D and commercialization of innovative therapies and novel drugs with accelerating international development. The following are achievements and milestones we have reached:

About Junshi Biosciences

Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Five of the company’s products have received approvals in China and international markets, one of which is toripalimab, China’s first domestically produced and independently developed anti-PD-1 monoclonal antibody. Toripalimab has been approved in 40 countries and regions including China, the US, and Europe. During the COVID-19 pandemic, Junshi Biosciences actively shouldered the social responsibilities of a Chinese pharmaceutical company through its involvement in developing etesevimab, MINDEWEI , and other novel therapies for the prevention and treatment of COVID-19.

With a mission of “providing patients with world-class, trustworthy, affordable, and innovative drugs,” Junshi Biosciences is “In China, For Global.” At present, the company boasts approximately 2,500 employees in the United States (Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc.). For more information, please visit: http://www.junshipharma.com.

Junshi Biosciences Contact Information
IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-6105 8800

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800